We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cencora to Acquire AON in $2.4B Deal to Expand Oncology Network
Read MoreHide Full Article
Key Takeaways
Cencora's $2.4B AON deal aims to expand its oncology MSO platform and strengthen community cancer care.
The deal will extend Cencora's reach across 12 additional states and add more than 350 oncology providers.
Cencora expects the deal to boost adjusted EPS in the second year after closing, subject to approvals.
Cencora, Inc. (COR - Free Report) recently announced a definitive agreement to acquire American Oncology Network (“AON”), a physician-led network of more than 350 oncology providers across 21 states. Cencora aims to expand its oncology management services organization (MSO) platform and strengthen support for community-based cancer care. The transaction values AON at an enterprise value of $2.4 billion, including $2.3 billion at closing and contingent value rights of up to $100 million.
Per management, the acquisition will broaden Cencora’s physician-led oncology MSO platform and extend its support for community-based cancer care nationwide. AON’s tailored solutions and established relationships with oncology practices are expected to complement Cencora’s existing MSO network, enhance independent practices, improve access to high-quality, cost-effective care and create opportunities for sustainable growth and long-term stakeholder value.
COR Stock Trend Following the News
COR stock has lost 4.4% since the announcement on Oct. 21. Year to date, the stock has fallen 3.7% against the industry’s 8.4% growth and the S&P 500’s 12% rise.
The acquisition could strengthen Cencora’s position in the oncology care ecosystem by broadening its relationships with community-based providers and increasing opportunities to support independent practices. A larger network may create additional avenues to deliver practice-management services and improve coordination across oncology care settings. If integration proceeds successfully, the expanded platform could support recurring business opportunities and contribute to earnings growth over time.
COR currently has a market capitalization of $62.97 billion.
Image Source: Zacks Investment Research
More on the News
Cencora already owns approximately 4% of AON and has agreed to acquire the remaining equity interests. If certain AON stockholders roll over up to 25% of their ownership into the combined structure, Cencora expects to pay approximately $1.7 billion at closing to raise its ownership to 75%. The transaction is expected to become accretive to Cencora’s adjusted earnings per share in the second year after closing.
Founded in 2018, AON provides community oncology practices with practice-management expertise, integrated ancillary services and other operational support. Its physician-led model is designed to help independent practices remain viable while enabling clinicians to focus on patient care. The network’s expansion would extend Cencora’s reach across 12 additional states and add complementary capabilities to its existing MSO platform.
The companies intend to continue supporting community-based cancer care, with AON physicians retaining responsibility for clinical decisions. The transaction remains subject to customary closing conditions, including regulatory clearances and AON stockholder approval.
Industry Prospects Favoring the Market
According to Research and Markets, the global community oncology services market is estimated to be valued at $58.99 billion in 2026 and is expected to witness a CAGR of 7.9% through 2030.
Factors such as the rising prevalence of cancer, increasing demand for accessible community-based cancer care, greater adoption of precision oncology therapies, expansion of outpatient cancer services and growing emphasis on value-based care are expected to drive market growth.
Other News
Cencora’s Accelerate Pharmacy Solutions launched Cell and Gene Therapy (CGT) Enablement, a service designed to help health systems assess, develop and expand CGT programs. The service provides financial assessments, reimbursement guidance, operational readiness evaluations, governance planning and scalable operating models. The initiative aims to strengthen program execution, reduce barriers to care and broaden patient access to advanced therapies. The company noted that more than 35 CGTs have received FDA approval, while a recent survey found only 4% of health-system pharmacy leaders considered their organizations fully prepared to integrate these therapies.
Currently, Cencora carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Intuitive Surgical (ISRG - Free Report) and Globus Medical (GMED - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
View the Zacks #1 Rank List
Image: Shutterstock
Cencora to Acquire AON in $2.4B Deal to Expand Oncology Network
Key Takeaways
Cencora, Inc. (COR - Free Report) recently announced a definitive agreement to acquire American Oncology Network (“AON”), a physician-led network of more than 350 oncology providers across 21 states. Cencora aims to expand its oncology management services organization (MSO) platform and strengthen support for community-based cancer care. The transaction values AON at an enterprise value of $2.4 billion, including $2.3 billion at closing and contingent value rights of up to $100 million.
Per management, the acquisition will broaden Cencora’s physician-led oncology MSO platform and extend its support for community-based cancer care nationwide. AON’s tailored solutions and established relationships with oncology practices are expected to complement Cencora’s existing MSO network, enhance independent practices, improve access to high-quality, cost-effective care and create opportunities for sustainable growth and long-term stakeholder value.
COR Stock Trend Following the News
COR stock has lost 4.4% since the announcement on Oct. 21. Year to date, the stock has fallen 3.7% against the industry’s 8.4% growth and the S&P 500’s 12% rise.
The acquisition could strengthen Cencora’s position in the oncology care ecosystem by broadening its relationships with community-based providers and increasing opportunities to support independent practices. A larger network may create additional avenues to deliver practice-management services and improve coordination across oncology care settings. If integration proceeds successfully, the expanded platform could support recurring business opportunities and contribute to earnings growth over time.
COR currently has a market capitalization of $62.97 billion.
Image Source: Zacks Investment Research
More on the News
Cencora already owns approximately 4% of AON and has agreed to acquire the remaining equity interests. If certain AON stockholders roll over up to 25% of their ownership into the combined structure, Cencora expects to pay approximately $1.7 billion at closing to raise its ownership to 75%. The transaction is expected to become accretive to Cencora’s adjusted earnings per share in the second year after closing.
Founded in 2018, AON provides community oncology practices with practice-management expertise, integrated ancillary services and other operational support. Its physician-led model is designed to help independent practices remain viable while enabling clinicians to focus on patient care. The network’s expansion would extend Cencora’s reach across 12 additional states and add complementary capabilities to its existing MSO platform.
The companies intend to continue supporting community-based cancer care, with AON physicians retaining responsibility for clinical decisions. The transaction remains subject to customary closing conditions, including regulatory clearances and AON stockholder approval.
Industry Prospects Favoring the Market
According to Research and Markets, the global community oncology services market is estimated to be valued at $58.99 billion in 2026 and is expected to witness a CAGR of 7.9% through 2030.
Factors such as the rising prevalence of cancer, increasing demand for accessible community-based cancer care, greater adoption of precision oncology therapies, expansion of outpatient cancer services and growing emphasis on value-based care are expected to drive market growth.
Other News
Cencora’s Accelerate Pharmacy Solutions launched Cell and Gene Therapy (CGT) Enablement, a service designed to help health systems assess, develop and expand CGT programs. The service provides financial assessments, reimbursement guidance, operational readiness evaluations, governance planning and scalable operating models. The initiative aims to strengthen program execution, reduce barriers to care and broaden patient access to advanced therapies. The company noted that more than 35 CGTs have received FDA approval, while a recent survey found only 4% of health-system pharmacy leaders considered their organizations fully prepared to integrate these therapies.
Cencora, Inc. Price
Cencora, Inc. price | Cencora, Inc. Quote
COR’s Zacks Rank & Key Picks
Currently, Cencora carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Intuitive Surgical (ISRG - Free Report) and Globus Medical (GMED - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.